logo
Scientists say they ‘brought back' dire wolves from extinction. Not exactly.

Scientists say they ‘brought back' dire wolves from extinction. Not exactly.

Washington Post08-04-2025

For over 2 million years, dire wolves roamed present day North America until their extinction around 10,000 B.C.
On Monday, a Dallas-based bioscience firm said it had brought the species back to life in the form of three pups, claiming to have 'successfully restored a once-eradicated species through the science of de-extinction' in a remarkable statement on its website.
The team at Colossal said the pups — named Khaleesi, Romulus and Remus, and ranging in age from 3 to 6 months old — were created using a combination of gene-editing techniques and ancient DNA found in fossils from between 11,500 and 72,000 years ago.
Other scientists, however, say that while Colossal's technological feats are impressive, the animals are not truly dire wolves — and that the process has raised a raft of ethical issues.
'The reality is we can't de-extinct extinct creatures because we can't use cloning — the DNA is just not well enough preserved,' said Nic Rawlence, an associate professor and director of the Palaeogenetics Laboratory at New Zealand's University of Otago.
In a phone interview Tuesday, he said Colossal's pups are not dire wolves, but gray wolves that have had part of their genome changed to look like dire wolves. 'What Colossal is trying to do is genetically engineering animals to look like extinct creatures,' he said. 'They look cute and cuddly but … they're not a dire wolf.'
Pontus Skoglund, leader of the Ancient Genomics Laboratory at Britain's Francis Crick Institute, said in a post on Bluesky that he was 'not necessarily against the initiative, but would a chimpanzee with 20 gene edits be human? … These individuals seem optimistically 1/100,000th dire wolf.'
Video posted on Colossal's social media showed two of the white fluffy pups, Romulus and Remus, practicing their howls. Romulus and Remus are the names of the mythical founders of Rome, who were raised by a wolf. Dire wolves will also be familiar to fans of 'Game of Thrones,' the hit television show, which features several of the animals. The name of the other pup, Khaleesi, appears in the 'Game of Thrones' TV and book series, which also depicts dire wolves.
The 'dire wolf' pups are the latest headline-grabbing claim from the bioscience venture founded by tech entrepreneur Ben Lamm and Harvard geneticist George Church, which says it is working to bring back some of the world's most famous extinct species.
In its sights are the woolly mammoth, the dodo and thylacine, or Tasmanian Tiger, which it aims to reengineer for the modern world. It has already created mice with hair like a woolly mammoth, and aims to conserve ancient traits as part of what it says are broader efforts to preserve the world's biodiversity. The company has been valued at $10.2 billion and raised $435 million in funding, including $200 million announced in January.
Colossal's chief science officer, Beth Shapiro, said in a statement on the company's website that the birth of the pups shows 'we are one step closer to a world in which these tools are among those at our disposal to help species thrive in their rapidly changing habitats.'
Shapiro, previously told The Washington Post that the company was not trying to clone animals in the same way that had been done with Dolly the Sheep. 'We're not trying to make something that's identical to a dodo,' Shapiro said about the company's efforts to create a dodo-like bird using the DNA of a pigeon. 'We're trying to create something that's able to behave like a dodo would on that landscape in some key, functional way. So a large, flightless bird that wanders around and eats fruits and spreads the seeds,' she said.
Some scientists are dismissive of the claims and wary of the company's approach, even while expressing admiration for the technological accomplishments of its CRISPR gene editing techniques — in which a piece of DNA can be snipped out from a genome and precisely replaced.
In the wolves' case, scientists edited the gray wolf genome to approximate the size, color and coat of a dire wolf, Rawlence said. 'There are about 19,000 genes in that genome. They looked at all the differences and said there are 20 key differences in 14 key genes that they could change to make a gray wolf look like a dire wolf,' he said. 'Their technology is amazing, but my personal view is it needs to be used to conserve the animals we've got left,' he said. This could include using money the company has raised to manage existing endangered species or reintroduce genetic diversity among existing species to help them adapt to climate change or diseases.
He said trying to re-create the characteristics of extinct animals provides no incentive to conserve species in the first place and raises concerns about where and how the animals will live. 'Is there even going to be the habitat? How are you going to deal with increased human-wolf conflict? What's going to happen when your genetically engineered gray wolves hybridize with other gray wolves?' he said.
He also raised concerns about how a species could survive with just three members and said 'at least 500 individuals' would be needed to ensure a genetically diverse population. He also raised ethical concerns: Will extinction companies trademark these creatures? Who owns them? These are all discussions we need to have,' he said.
Colossal did not immediately respond to a request for comment Tuesday morning.
Michael Knapp, an associate professor at the University of Otago's department of anatomy, agreed the topic raises a raft of ethical questions but said the birth of the pups is a 'major breakthrough in genetics.'
'It is easy to brush attempts to bring back extinct species off as vanity projects without purpose in the real world, but that would ignore the technological breakthroughs behind these efforts,' he said in a statement. 'Whether or not this is an avenue that should be further pursued is a highly complex question.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Texas to expand psychedelic research with $50M ibogaine investment
Texas to expand psychedelic research with $50M ibogaine investment

Yahoo

time3 hours ago

  • Yahoo

Texas to expand psychedelic research with $50M ibogaine investment

AUSTIN (KXAN) — Texas Gov. Greg Abbott is holding a bill signing ceremony Tuesday for legislation that invests $50 million into clinical research of ibogaine — a naturally occurring psychedelic substance that could treat post-traumatic stress disorder, opioid use disorder and other mental health conditions. For years, veterans and others suffering from PTSD have sought ibogaine treatment in Mexico, where the substance is not heavily regulated. In the United States, ibogaine is classified as a Schedule 1 drug, the most restrictive drug category. Other drugs classified under Schedule 1 include psilocybin, LSD and heroin. According to the legislative summary of SB 2308, the implications for those with opioid use disorder are lifechanging; a single administration of ibogaine in a controlled setting has been shown to stop withdrawal symptoms and reduce drug cravings long-term. RELATED: Lawmakers hope to expand medical marijuana program as state bans intoxicating hemp products 'Preliminary reports also suggest benefits in cognitive function, mood regulation, and sleep among individuals with [traumatic brain injury] and PTSD—conditions prevalent among U.S. veterans,' the bill text read. The new legislation will create a program within the Texas Health and Human Services Commission to support Texas-based trials of ibogaine through the FDA. Ibogaine is not currently FDA-approved due to its Schedule 1 classification. SB 2308 will fund research through gifts, grants or donations and will require equal matching funds by the recipients, which will include Texas medical facilities 'equipped for cardiac-intensive monitoring' by a supervising physician, among other qualifications. 'By advancing ibogaine research, Texas has the opportunity to lead in neuroscience innovation, address urgent veteran health needs, and shape the future of mental health treatment nationwide,' the bill text reads. While legislation aimed at easing access to ibogaine moves forward, separate legislation to restrict access to another plant has also progressed. Texas lawmakers sent a bill banning non-medical THC products to Abbott for approval late last month. Still, Texas in recent years has become more open-minded to the use of psychedelic substances in treating mental health conditions. 'There's definitely been a shift in the openness and the receptivity of the field to this type of research,' said Greg Fonzo, Ph.D., co-director of the McGill Center for Psychedelic Research & Therapy at Dell Medical School. 'People who do undergo this treatment process, some of them respond well and have a benefit in terms of symptom reductions and feeling better,' Fonzo told KXAN earlier this year. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Watch: Gaal takes on the Mule in 'Foundation' Season 3 trailer
Watch: Gaal takes on the Mule in 'Foundation' Season 3 trailer

UPI

time4 hours ago

  • UPI

Watch: Gaal takes on the Mule in 'Foundation' Season 3 trailer

1 of 3 | Apple TV+ is previewing Season 3 of "Foundation." Photo courtesy of Apple TV+ June 11 (UPI) -- Voyagers actress Lou Llobell and Game of Thrones actor Pilou Asbaek prepare to face off in a new trailer for Foundation Season 3, released Wednesday. Llobell portrays Gaal in the sci-fi series inspired by the Isaac Asimov novels. Asbaek joins the cast as the Mule, a warlord who poses "a threat to the entire galaxy," according to an official synopsis. "You think I'm a monster?" he asks in the preview. "I have talents, you see. I can worm my way into people's minds. Convert enemies into allies. Hate into love." Hari (Jared Harris) tells Gaal that her battle is with the Mule. "It's my job to ensure you're prepared." he says. "The Mule's abilities are far beyond anything I can do," she responds. Season 3 takes place more than a century after Season 2, according to the synopsis. The upcoming chapter also stars Cherry Jones, Brandon P. Bell, Synnove Karlsen, Cody Fern, Tomas Lemarquis, Alexander Siddig, Troy Kotsur, Laura Birn, Cassian Bilton, Terrence Mann and Rowena King. Season 3 premieres July 11 on Apple TV+.

Somnee raises $10m for AI neurotech sleep wearables
Somnee raises $10m for AI neurotech sleep wearables

Yahoo

time7 hours ago

  • Yahoo

Somnee raises $10m for AI neurotech sleep wearables

US-based Somnee has secured $10m in a seed extension round to advance its AI-powered neurotech sleep wearables. The funding will aid the launch of the company's second-generation smart sleep headband. Khosla Ventures spearheaded the round with contributions from Marc Benioff's TIME Ventures, the DeVos family of the NBA's Orlando Magic, LEAD VC, Seaside Ventures, Metalab, and Nelstone Ventures. Based on sleep research and neuroscience, the company developed the headband that utilises AI technology and electroencephalogram (EEG+) to map the brain activity of users and provide personalised stimulation. This headband is said to aid individuals in falling asleep quickly, extending their sleep duration, and minimising restlessness. In a study, the headband demonstrated superiority over melatonin, Ambien, and cognitive behavioural therapy for insomnia (CBT-i). The headband features SmartSleep AI operating system, which will offer real-time monitoring and AI-driven interventions tailored to individual sleep patterns. Somnee's product is currently undergoing beta testing with certain NBA [National Basketball Association] teams and the performance training staff. Founded in 2022 by Dr Matt Walker and a team from the University of California, the company has seen significant progress under CEO Tim Rosa, who joined 18 months ago. Somnee is actively seeking further collaborations with professional sports teams, employers, as well as brands focusing on healthcare to leverage research that connects sleep quality with athletic performance, longevity, and productivity. Dr Walker said: 'We're trying to speak to the brain in its own language – using gentle, precisely timed pulses of electricity, not unlike how a conductor uses subtle hand movements to guide an orchestra into harmony. 'The goal was to create what I call a 'blast radius' of benefit: deeper sleep, more efficient sleep, and a quicker descent into sleep itself by preparing the brain just before sleep, we're trying to drive more powerful deep-sleep brainwaves, and give you a faster entry into sleep to begin with.' Last year, Somnee introduced an upgraded app and new features for its smart sleep headband. "Somnee raises $10m for AI neurotech sleep wearables" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store